Kailera Therapeutics

KLRA · Nasdaq Filing snapshot

Kailera Therapeutics is a clinical-stage biotech developing a pipeline of obesity and metabolic therapies. Its lead candidate, KAI-9531, is a once-weekly injectable GLP-1/GIP receptor dual agonist in-licensed from China's Hengrui Pharmaceuticals (known there as HRS9531); KAI-7535 is a once-daily oral GLP-1 small molecule. The company has not generated revenue. Its $16.00 Nasdaq IPO raised about $625M gross, with Bain Capital and the Qatar Investment Authority among existing investors indicating interest. The filing names a dozen obesity rivals, led by Novo Nordisk (Wegovy) and Eli Lilly (Zepbound).

Listed

Apr 17, 2026

Raised

$625M

Sector

Biotechnology · Obesity & Metabolic · Pharmaceuticals

Named rivals

12 in the S-1

Named in the S-1 12 named

Kailera Therapeutics

KLRA · the filer

Eli Lilly

named 15×

Merck

named 9×

Novo Nordisk

named 8×

Amgen

named 6×

Pfizer

named 5×

AstraZeneca

named 5×

Zealand Pharma

named 4×

Structure Therapeutics

named 2×

Viking Therapeutics

named 2×

Boehringer Ingelheim

named 2×

Roche

named 2×

QL Biopharma

named 1×

“

The read

A Bain Capital- and Qatar-backed obesity challenger whose lead drug is in-licensed from China's Hengrui — taking on the GLP-1 duopoly. The S-1 names a dozen rivals, led by Eli Lilly (Zepbound) and Novo Nordisk (Wegovy). No revenue yet; a $625M war chest.

Want the full picture on Kailera Therapeutics?

Request the deep Exposure Report — share-of-presence, a 90-day signal timeline, and the white space these 12 rivals leave open. We build it within 48 hours.

Request full coverage